Literature DB >> 31476872

The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease.

Cristina Suárez Ferrer1, Marta Abadía Barno2, Eduardo Martín Arranz2, Andrea Jochems3, Laura García Ramírez2, Joaquín Poza Cordón4, Marta Jaquotot Herranz2, Alberto Cerpa Arencibia5, María Dolores Martín Arranz2.   

Abstract

INTRODUCTION: simple, reliable and non-invasive biomarkers are needed to enable the early detection of inflammatory activity for the correct management of inflammatory bowel disease (IBD). One of these biomarkers may be serum calprotectin (SC).
MATERIAL AND METHODS: a prospective study was performed of patients with IBD due to undergo a colonoscopy as part of the common clinical practice. The study parameters included SC, fecal calprotectin (FC) and conventional blood test parameters. Clinical indices (Harvey and Walmsley) and relevant endoscopic scores were completed for each scenario (Simple Endoscopic Score Crohn Disease [SES-CD] and Mayo).
RESULTS: fifty-three patients were included in the study, 51% (27 patients) with ulcerative colitis (UC) and 49% (26 patients) with Crohn's disease (CD). The CS values in UC were significantly higher with an endoscopic Mayo score 2/3 (median score 10.39 mg/ml [IQR: 7.4-12.2]) compared to those with a Mayo score of 0/1 (median 4.07 mg/ml [IQR: 2.9-7.2]) (p = 0.01). The area under the ROC curve (AUCROC) was 0.85 and the sensitivity and specificity were 83.3% and 81.25%, respectively, for a SC cut-off point of 4.4 mg/dl. Furthermore, a higher AUCROC was obtained in comparison with other serological markers for activity (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], hemoglobin [Hb] and platelets). There were no statistically significant differences in the comparison between SC and endoscopic findings in CD (SES CD > 3: 20.1 [IQR: 16.8-23.4] vs SESC ≤ 3:6.25 [IQR: 5.4-7.1]) (p = 0.8).
CONCLUSIONS: SC is a good indirect marker of inflammatory activity and there was a correlation with endoscopic findings in UC. However, there were no statistically significant differences in the case of CD.

Entities:  

Year:  2019        PMID: 31476872     DOI: 10.17235/reed.2019.5797/2018

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  3 in total

1.  The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease.

Authors:  Yi-Han Chen; Li Wang; Shu-Yi Feng; Wei-Min Cai; Xiao-Fu Chen; Zhi-Ming Huang
Journal:  Gastroenterol Res Pract       Date:  2020-06-22       Impact factor: 2.260

2.  A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn's Disease.

Authors:  Shaun S Ho; Catherine Wall; Richard B Gearry; Jacqueline Keenan; Andrew S Day
Journal:  Inflamm Intest Dis       Date:  2020-10-14

3.  Patient knowledge of fecal calprotectin in inflammatory bowel disease (IBD): An observational study in Mexico.

Authors:  Brenda Maldonado-Arriaga; Sergio Sandoval-Jiménez; Juan Rodríguez-Silverio; Sofía Lizeth Alcaráz-Estrada; Tomás Cortés-Espinosa; Rebeca Pérez-Cabeza de Vaca; Jonathan Shaw; Paul Mondragón-Terán; Cecilia Hernández-Cortez; Juan Antonio Suárez-Cuenca; Graciela Castro-Escarpulli
Journal:  F1000Res       Date:  2020-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.